Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer

BACKGROUND: In this study, we evaluated real-world data on radium-223 plus abiraterone/prednisone or enzalutamide. Previously, the ERA 223 trial (NCT02043678) demonstrated increased fracture risk with concurrent treatment with radium-223 and abiraterone plus prednisone/prednisolone in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal, Higano, Celestia S., George, Daniel J., Sternberg, Cora N., Saad, Fred, Tombal, Bertrand, Miller, Kurt, Kalinovsky, Jan, Jiao, XiaoLong, Tangirala, Krishna, Sartor, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655504/
https://www.ncbi.nlm.nih.gov/pubmed/32404868
http://dx.doi.org/10.1038/s41391-020-0236-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7655504/
https://www.ncbi.nlm.nih.gov/pubmed/32404868
http://dx.doi.org/10.1038/s41391-020-0236-0

Ejemplares similares